08:30-08:50 | Registration |
08:50-09:00 | Opening Remark |
| Session I-1.NGS ÁÂÀå : À̰DZ¹ (±¹¸³¾Ï¼¾ÅÍ) | Session I-2. Lung cancer genomicsÁÂÀå : Àå¼¼Áø (¿ï»êÀÇ´ë) |
---|
09:00-09:20 | NGS±â¹Ý À¯ÀüÀÚ ÆÐ³Î°Ë»çÀÇ Áú°ü¸®¼Õ´ë¼ø (»ï¼ºÀ¯Àüü ¿¬±¸¼Ò) | 09:00-09:30 | NGS data -based Artificial Intelligence Model for Cancer-Drug-Response Profiling Á¤Á¾¼± (½ÅÅ×Ä« ¹ÙÀÌ¿À) |
09:20-09:40 | NGS ±â¹Ý À¯ÀüÀÚ ÆÐ³Î °Ë»ç ±Þ¿©È ¹è°æ ¹× Àü¸Á½ÉÈ¿¼· (¿¬¼¼ÀÇ´ë) | 09:30-10:00 | Study for cancer genomics; whats left?±èÁÖÇÑ (¼¿ï´ë) |
09:40-10:00 | NGS ±â¹Ý À¯ÀüÀÚ ÆÐ³Î °Ë»çÀÇ ±â°üº° »óȲ ¹× Àü¸Á I±èÁöÈÆ (¿ï»êÀÇ´ë) | 10:00-10:30 | Genomic data sharing; implications & hurdlesÁ¤¿¬ÁØ(°¡Å縯ÀÇ´ë) |
10:00-10:20 | NGS ±â¹Ý À¯ÀüÀÚ ÆÐ³Î °Ë»çÀÇ ±â°üº° »óȲ ¹× Àü¸Á II±èÅÂÁ¤ (°¡Å縯ÀÇ´ë) | |
10:20-10:30 | Q&A | |
10:30-11:00 | Coffee Break |
| Plenary Session ÁÂÀå : Á¶¹®ÁØ (Ãæ³²ÀÇ´ë) |
---|
11:00-11:50 | The Healthcare Innovation for the precision cancer medicine with IBM Watson Health? Annette Hicks (Watson Health, IBM) |
11:50-12:00 | Q&A |
| Luncheon Symposium IÁÂÀå : ±è»óÀ§ (¿ï»êÀÇ´ë) |
---|
12:00-12:40 | Big Stride in 1L NSCLC treatment: moving from chemotherapy to anti- PD 1 therapy (MSD)Raffaele Califano (The Christie NHS Foundation Trust and University Hospital of South Manchester) |
12:40-13:00 | Coffee Break |
| Oral Presentation |
---|
13:00~13:10 | Chemopreventive effect of long-term use of low-dose aspirin on lung cancer risk A nationwide study considering competing risk õÀº¹Ì (ÀÌÈÀÇ´ë) | 13:00~13:10 | Weekly Docetaxel as first-line chemotherapy in elderly patients with advanced squamous cell non-small cell lung cancer : phase II study ÃÖÁ¾Çö (°í·ÁÀÇ´ë) | 13:00~13:10 | Æó¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î °³ÀÎ ¸ÂÃãÇü È£Èí ÀçȰ ¼ºñ½º(¼ûư PHR¢ç)ÀÇ ÀÓ»óÀû È¿°ú¸¦ È®ÀÎÇϱâ À§ÇÑ ÀüÇâÀû ¿¬±¸ Áö¿øÁØ (¿ï»êÀÇ´ë) |
13:10~13:20 | Bone Metastasis is associated with Osteoporosis Risk Among Lung Cancer Patients À̽·æ (°í·ÁÀÇ´ë) | 13:10~13:20 | Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer ¹Ú¼ÛÀÌ (¼º±Õ°üÀÇ´ë) | 13:10~13:20 | Generative Model of Functional RT-Plan Chest CT for Lung Cancer Patients Using Machine Learning Algorithm Àå¹ü¼· (¼¿ïÀÇ´ë) |
13:20~13:30 | Role of low-dose computerized tomography in lung cancer screening among never-smokers °Çý¸° (¼¿ïÀÇ´ë) | 13:20~13:30 | Clinical characteristics of lung cancer with programmed death-ligand 1 expression ¹ÚÇÏ¿µ (Àü³²ÀÇ´ë) | 13:20~13:30 | Generation of predicted tumor-regression computed tomography image during definitive concurrent chemo-radiotherapy of the lung cancer using deep learning technique ±è°æ¼ö (µ¿³²±Ç¿øÀÚ·ÂÀÇÇпø) |
13:30~13:40 | Comparison of PD-L1 Expression on Cell Block and Matched Resection Specimens from Lung Cancer ³ë¹Ì¼÷ (µ¿¾ÆÀÇ´ë) | 13:30~13:40 | Continuing Gefitinib beyond progression in patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A phase II single-arm prospective trial ÀÓ¼º¿ø (¼º±Õ°üÀÇ´ë) | 13:30~13:40 | Initial PET/CT maximal SUV as a Biologic Predictive Factor Prognostic of Outcome in Early-stage NSCLC after SABR °ûÀ¯° (°¡Å縯ÀÇ´ë) |
13:40~13:50 | Extracellular vesicle DNA for liquid biopsy ÇãÀ翵 (°Ç±¹ÀÇ´ë) | 13:40~13:50 | Outcomes of T790M+ lung cancer patients treated with osimertinib in real world practice after acquired resistance to the previous EGFR-TKI in Korea ¿Àµ¿±Ô (¿ï»êÀÇ´ë) | 13:40~13:50 | Exosomes Increase More at Pulmonary Vein than Peripheral Vessel in Lung Cancer: based on preclinical and clinical studies ±èÇö±¸ (°í·ÁÀÇ´ë) |
13:50~14:00 | Detection and dynamic change of EGFR mutation status in plasma and comparison of tissue from NSCLC patients ÀÌÀ±°æ (¿ï»êÀÇ´ë) | 13:50~14:00 | Phase II Trial of AZD9291 in Second-Line Treatment after Acquired Resistance with T790M Mutation Detected From Circulating Tumor DNA (LiquidLung-O-Cohort 2) ±è¿µÃ¶ (Àü³²ÀÇ´ë) | 13:50~14:00 | Prognostic Factor and Survival of Patients with Resected stage IIIA N2 Lung Adenocarcinoma ±èÁ¦ÈÆ (¿ï»êÀÇ´ë) |
14:00~14:10 | Feasibility and alternative approaches of rebiopsy in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors ±èÈñÁ¤ (°Ç±¹ÀÇ´ë) | 14:00~14:10 | Tumor-derived microvesicles promote the immune surveillance of tumor through PD-1/PD-L1 interaction ±èµ¿ÇÏ (¿ï»êÀÇ´ë) | 14:00~14:10 | Feasibility of lobectomy and mediastinal node dissection by video-assisted thoracoscopic surgery following neoadjuvant?chemoradiaotherapy for stage IIIA N2?lung cancer: Propensity matching analysis Àü¿µÁ¤ (¼º±Õ°üÀÇ´ë) |
14:10~14:20 | Feasibility of Liquid Biopsy Using Plasma and Platelets for Detection of ALK Rearrangements in Non-Small Cell Lung Cancer ¹Úö±Ô (Àü³²ÀÇ´ë) | 14:10~14:20 | Glucose Supports EGFR-mutant Lung Adenocarcinoma Cell Survival by Inhibiting Autophagy-mediated EGFR Degradation ³ëÁø°æ (¿ï»êÀÇ´ë) | 14:10~14:20 | Diffusing capacity(DLco) decrement following neoadjuvant concurrent chemoradiotherapy :implication on postoperative pulmonary complications in lung cancer patients ½Å¼ö¹Î (¼º±Õ°üÀÇ´ë) |
14:20-14:40 | Coffee Break |
| Session II-1. In-depth review of 8th TNM staging ÁÂÀå : ÀÌÃáÅà (¼¿ïÀÇ´ë) | Session II-2. Screen-detected Ground Glass NodulesÁÂÀå : ³ª±¹ÁÖ (Àü³²ÀÇ´ë) | Session II-3. Emerging field of Radiomics ÁÂÀå : ¿ëȯ¼® (°í·ÁÀÇ´ë) |
---|
14:40-15:05 | TNM staging; pulmonologists perspectiveȲº¸ºó (±¹¸³¾Ï¼¾ÅÍ) | 14:40-15:00 | Management strategy and guideline: follow-up vs. surgeryÀüÀçÇö (±¹¸³¾Ï¼¾ÅÍ) | Basics of image processing in radiomics ±è³²±¹ (¿ï»êÀÇ´ë) |
15:05-15:30 | TNM staging; radiologists perpective¾È¸íÀÓ (°¡Å縯ÀÇ´ë) | 15:00-15:20 | Preoperative workup: Bronchoscopy/EBUS, brain MRI, PET/ CT, Biopsy are needed?Á¶Á¤¼ö (ºÎ»êÀÇ´ë) | Radiomics: the current statusÀÌÈ£¿¬ (¼º±Õ°üÀÇ´ë) |
15:30-15:55 | TNM staging; surgeons perspectiveÀÌÁø±¸ (¿¬¼¼ÀÇ´ë) | 15:20-15:40 | Localization techniqueÁ¶¼®±â (¼¿ïÀÇ´ë) | Radiomics and beyond: limitations and future directions¹Úâ¹Î (¼¿ïÀÇ´ë) |
15:55-16:10 | Q&A | 15:40-16:00 | Surgical procedure: Optimal extent of pulmonary resection and mediastinal LN assessment±èÈ«°ü (¼º±Õ°üÀÇ´ë) | Q&A |
16:00-16:10 | Q&A | |
16:10-16:40 | Coffee Break |
| Session III-1. Neuroendocrine tumors other than SCLCÁÂÀå : ±è°ü¹Î (¼¿ïÀÇ´ë) | Session III-2. Thymic Epithelial Tumors ÁÂÀå : ¿À¿µÅà (¾ÆÁÖÀÇ´ë) | Session III-3. SCLC
ÁÂÀå : ¾È¸íÁÖ (¼º±Õ°üÀÇ´ë) |
---|
16:40-17:00 | Pathology of neuroendocrine tumorÇϽ¿¬ (°¡ÃµÀÇ´ë) | Review of staging and pathologic classification³ë¹Ì¼÷ (µ¿¾ÆÀÇ´ë) | Novel chemotherapeutic agent in SCLC±èÇý·Ã (¿¬¼¼ÀÇ´ë) |
17:00-17:20 | Surgery±èÇü·Ä (¿ï»êÀÇ´ë) | Recent updates of chemotherapy¾ÈÈñ°æ (°¡ÃµÀÇ´ë) | Role of radiation therapy in extensive disease SCLC±èÇÐÀç (¼¿ïÀÇ´ë) |
17:20-17:40 | Chemotherapy for large cell neuroendocrine carcinoma¼±Á¾¹« (¼º±Õ°üÀÇ´ë) | Radiotherapy for Thymic Tumors¼Û»óÇõ (°¿øÀÇ´ë) | Role of surgery in SCLCÀÌÈ£¼® (ºÎ»êÀÇ´ë) |
17:40-18:00 | Coffee Break |
| Dinner Symposium (Sapphire room)ÁÂÀå : ±è¿µÃ¶ (Àü³²ÀÇ´ë) |
---|
18:00-18:50 | Recent update with clinical practice of Atezolizumab in NSCLC (Roche)ÇÑÁö¿¬ (±¹¸³¾Ï¼¾ÅÍ) |